Studies with [68Ga]Ga-labeled or [18F]F-labeled fibroblast activation protein inhibitor compounds have demonstrated favorable characteristics for PET/CT imaging, making them especially interesting for digestive tumors. In this review, the recent evidence in this field and its potential clinical applications are discussed.
Bolton R.C.D., Calapaqui Teran A.K., Herrmann K., Fanti S., Giammarile F. (2023). Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors with the Clinical Application of FAPI Imaging?. CLINICAL NUCLEAR MEDICINE, 48(4), 318-319 [10.1097/RLU.0000000000004602].
Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors with the Clinical Application of FAPI Imaging?
Fanti S.;
2023
Abstract
Studies with [68Ga]Ga-labeled or [18F]F-labeled fibroblast activation protein inhibitor compounds have demonstrated favorable characteristics for PET/CT imaging, making them especially interesting for digestive tumors. In this review, the recent evidence in this field and its potential clinical applications are discussed.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
